Pharnext announces the extension of the conciliation procedure until July 15, 2024

Pharnext, a French biopharmaceutical company, announced the extension of its conciliation procedure until July 15, 2024. This decision, approved by the Commercial Court at the request of Pharnext and with the support of the conciliator, will allow the company to continue its activities while awaiting the results of a Phase III clinical study in China. This study, conducted by partner Tasly through a joint venture, concerns PXT3003, a drug candidate for Charcot-Marie-Tooth disease type 1A.

Pharnext management has communicated with Tasly representatives and anticipates an announcement of the results soon. In addition, all voting results from the General Meeting of June 10, 2024 are available on the Company's website, showing the massive adoption of the proposed resolutions.